Spoken Alpha
PROKIDNEY CORP.
ProKidney Corp. develops rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes.
PROKIDNEY CORP is a Healthcare company operating in Biotechnology with a $762.4M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PROK.
$ curl https://api.spokenalpha.com/v1/companies/PROKFAQ
Spoken Alpha indexes PROK's earnings call transcripts at https://spokenalpha.com/companies/PROK. Each call links to attributed speakers and parsed analyst Q&A. PROKIDNEY CORP.'s own investor relations page is at https://investors.prokidney.com/.
PROKIDNEY CORP. (PROK) held its most recent earnings call on 2023-11-16, covering fiscal Q3 2023.
PROKIDNEY CORP. (PROK) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-0.12 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-0.15 | $-0.13 | -15.4% | $150.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-0.14 | $-0.14 | -1.8% | $226.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-17 | $-0.14 | $-0.15 | +6.7% | $225.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.12 | $-0.14 | +14.3% | $217.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.13 | $-0.14 | +7.1% | $221.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.13 | $-0.16 | +18.8% | $230.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.17 | $-0.15 | -13.3% | $76.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.14 | $-0.22 | +36.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-0.16 | $-0.18 | +11.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.16 | $-0.18 | +11.1% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-21 | $-0.09 | $-0.17 | +47.1% | $4.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.18 | $-0.14 | -28.6% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.14 | $-0.41 | +65.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.16 | $-0.12 | -33.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-27 | $-0.11 | $-0.24 | +54.2% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.13 | $-0.31 | +58.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.06 | $-0.06 | +7.0% | $337.6K | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.12 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.06 | — | — | $0 | — | — | EODHD |
Source: EODHD. PROK reported actuals as published; sparse fields render as —.